Correction to Appendix 4C and Quarterly Activities Report
Filed with ASX · · 7 pages · English
Summary by 6ix AI
The correction clarifies that there were net cash inflows from operating activities, contrary to the previous statement of outflows. Additionally, the cash balance at the end of the quarter has been updated to reflect a higher amount than previously reported.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Patient Dosing Complete in Phase II ABSSSI Trial of R327G
- Regulatory Approval for Registrational Phase 3 R327G Trial
- Australia Patent Granted for RECCE Anti-Infectives
- AUD $6.75m R&D Rebate Approved
- Ethics Approval for Registrational Ph3 R327G Clinical Trial
Later from Recce Pharmaceuticals
- Pause in Trading
- Trading Halt
- Positive Phase II Data from Clinical Trial of R327 Gel
- Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway
- Japan Patent Allowance for RECCE Anti-Infectives
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals